Anixa Biosciences Inc. announced that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,370,244 on July 29, 2025, covering significant aspects of its breast cancer vaccine technology. The patent protects innovative methods for immunizing patients against breast cancer using an immunogenic composition containing human α-lactalbumin protein. This development extends Anixa's intellectual property protection for its breast cancer vaccine program into the mid-2040s, reinforcing the company's position in preventive oncology. The vaccine, developed in collaboration with Cleveland Clinic, targets a substantial unmet need in cancer prevention, particularly for women at high risk of developing triple-negative breast cancer (TNBC).
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。